Overall goals of our continuing program are to identify and develop anticancer clinical trial candidates, based on lead compounds that are isolated by using focused disease-oriented cytotoxicity, mechanistic, and molecular target based screening of selected medicinal plants, chosen either for their therapeutic use to treat cancer(s) or their structural novelty and potency. The fundamental aim of the proposed research is to discover novel anticancer drugs targeted primarily at key signal transduction pathways that regulate cell division, death, and differentiation. The following specific studies will be carried out to accomplish our goals. 1) Bioactivity-directed fractionation and isolation of the active principles from 30 high priority plant extracts will be continued. Our screening approach has been refined to stress molecular targets and several important signal transduction pathways and systems/elements of cellular differentiation and apoptosis. Two (2) important growth factor receptor tyrosine kinases (EGFR and HER-2) have been added as a new and complementary research initiative. 2) Structural characterization of new active leads will be done by chemical, physical, and spectral techniques. 3) Leads with significant activity will be selected for modification and analog synthesis to determine structure-activity relationships (SAR) as well as to improve pharmacological profiles. Conventional SAR, molecular modeling, and combinatorial chemistry techniques are used to aid lead generation and optimization. Compounds/plants of priority interest for investigation include breast cancer actives (e.g., neotanshinlactone and analogs, new active constituents of Quassia gabonensis), prostate cancer actives (new curcumin analogs), and differentiation/apoptosis inducers (new water-soluble dithiophene derivatives). 4) Subsequent in-depth mechanism of action studies and additional in vitro and in vivo antitumor evaluation will be performed by the National Institutes of Health (NIH) at the National Cancer Institute (NCI) as well as several corporate and academic collaborators. Our program has advantages of 1) an excellent supply of highly active lead compounds and promising cytotoxic plant species, including rainforest species from the NCI Natural Product Repository Program (NCI-NPRP), (2) excellent productivity in isolation and structural modification of new leads with new mechanisms of action as clinical trials candidates, which in turn could lead to innovative methods for cancer chemotherapy, and (3) a superior prospect for the successful development of a clinically useful drug, as several technologies have been licensed by corporate collaborators and are now undergoing further in vitro and in vivo preclinical and clinical assessment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA017625-29
Application #
7076964
Study Section
Synthetic and Biological Chemistry B Study Section (SBCB)
Program Officer
Fu, Yali
Project Start
2005-06-10
Project End
2010-04-30
Budget Start
2006-06-01
Budget End
2007-04-30
Support Year
29
Fiscal Year
2006
Total Cost
$301,855
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lu, Yan; Li, Yu-Quan; Liu, Yi-Nan et al. (2013) Cytotoxic and potential anticancer constituents from the stems of Schisandra pubescens. Pharm Biol 51:1204-7
Wang, Xiao-Feng; Wang, Sheng-Biao; Ohkoshi, Emika et al. (2013) N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin. Eur J Med Chem 67:196-207
Wang, Xiao-Feng; Ohkoshi, Emika; Wang, Sheng-Biao et al. (2013) Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors. Bioorg Med Chem 21:632-42
Chen, Min; Xu, Xiumei; Xu, Bing et al. (2013) Neglschisandrins E-F: two new lignans and related cytotoxic lignans from Schisandra neglecta. Molecules 18:2297-306
Wang, Qi; Chen, Tzu-Hsuan; Bastow, Kenneth F et al. (2013) Songaricalarins A-E, Cytotoxic Oplopane Sesquiterpenes from Ligularia songarica. J Nat Prod 76:305-10
Ye, Deyong; Shi, Qian; Leung, Chung-Hang et al. (2012) Antitumor agents 294. Novel E-ring-modified camptothecin-4?-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. Bioorg Med Chem 20:4489-94
Chen, Ying; Liu, Hong-Rui; Liu, Hong-Shan et al. (2012) Antitumor agents 292. Design, synthesis and pharmacological study of S- and O-substituted 7-mercapto- or hydroxy-coumarins and chromones as potent cytotoxic agents. Eur J Med Chem 49:74-85
Hung, Hsin-Yi; Nakagawa-Goto, Kyoko; Tokuda, Harukuni et al. (2012) Cancer preventive agents 11. Novel analogs of dimethyl dicarboxylate biphenyl as potent cancer chemopreventive agents(†). Pharm Biol 50:18-24
Shi, Qian; Wada, Koji; Ohkoshi, Emika et al. (2012) Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens. Bioorg Med Chem 20:4020-31
Dong, Yizhou; Nakagawa-Goto, Kyoko; Lai, Chin-Yu et al. (2012) Antitumor agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h]chromen-2-one and 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility. J Nat Prod 75:370-7

Showing the most recent 10 out of 282 publications